{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:00:08Z","timestamp":1773504008556,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH","award":["HL036444, CA076930, and CA15704"],"award-info":[{"award-number":["HL036444, CA076930, and CA15704"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbmt.2011.06.013","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T11:18:14Z","timestamp":1309951094000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients"],"prefix":"10.1016","volume":"18","author":[{"given":"Rosa F.","family":"Yeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Pawlikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul V.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.06.013_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2011.06.013_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425250903107764","article-title":"Busulfan in hematopoietic stem cell transplant setting","volume":"5","author":"McCune","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bbmt.2011.06.013_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2011.06.013_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbmt.2005.12.028","volume":"12","author":"Kletzel","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-3-36","article-title":"Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia","volume":"3","author":"Pidala","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2011.06.013_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u201cideal\u201d body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bbmt.2011.06.013_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-005-0029-0","article-title":"Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study","volume":"57","author":"Nguyen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2011.06.013_bib8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1177\/0091270009357430","article-title":"Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration","volume":"50","author":"Salinger","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2011.06.013_bib9","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood.V93.12.4436","article-title":"The impact of obesity and disease on busulfan oral clearance in adults","volume":"93","author":"Gibbs","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.06.013_bib10","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib11","doi-asserted-by":"crossref","unstructured":"Rezvani A, Storer B, McCune J, Batchelder A, McDonald G, Deeg H. Low toxicity and non-relapse mortality with reversed-order conditioning (cyclophosphamide followed by busulfan) in allogeneic hematopoietic cell transplantation. Poster Presentation at American Society of Hematology, 2009. New Orleans, LA. Abstract #1175.","DOI":"10.1182\/blood.V114.22.1175.1175"},{"key":"10.1016\/j.bbmt.2011.06.013_bib12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.06.013_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2404010","article-title":"Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis","volume":"20","author":"Scott","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.06.013_bib15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":"High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2007.06.005","article-title":"Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation","volume":"13","author":"Ryu","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2010.06.017","article-title":"Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination","volume":"17","author":"Almog","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","article-title":"Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens","volume":"28","author":"Bleyzac","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.06.013_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e318039b478","article-title":"Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study","volume":"29","author":"Bertholle-Bonnet","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2011.06.013_bib22","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-05-2079","article-title":"Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach","volume":"12","author":"Salinger","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2011.06.013_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2011.06.013_bib24","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:43:30Z","timestamp":1761057810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1083879111002837"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}